Abstract | BACKGROUND: METHODS: A systematic search was conducted on studies in PubMed, EMBASE, and Web of Science up to March 10, 2022. The quality of all included studies was assessed using the Newcastle-Ottawa Scale. The hazard ratio (HR) and its 95% confidence interval (95% CI) were extracted to analyze the association between H. pylori infection and prognosis of gastric cancer. In addition, subgroup analysis and publication bias were performed. RESULTS: A total of 21 studies were involved. The pooled HR was 0.67 (95% CI, 0.56-0.79) for overall survival (OS) in H. pylori-positive patients, with the control (HR = 1) being the H. pylori-negative group. In the subgroup analysis, the pooled HR was 0.38 (95% CI, 0.24-0.59) for OS in H. pylori-positive patients who received surgery combined with chemotherapy. The pooled HR for disease-free survival was 0.74 (95% CI, 0.63-0.8) and 0.41 (95% CI, 0.26-0.65) in patients who received surgery combined with chemotherapy. CONCLUSION: H. pylori-positive gastric cancer patients have a better overall prognosis than H. pylori-negative patients. H. pylori infection has improved the prognosis of patients undergoing surgery or chemotherapy, among which the improvement was most obvious in patients undergoing surgery combined with chemotherapy.
|
Authors | Chenxiao Gan, Xueping Wu, Yu Shen, Zhongsheng Cao, Jiyong Jing, Wensheng Pan |
Journal | Digestive diseases (Basel, Switzerland)
(Dig Dis)
Vol. 41
Issue 4
Pg. 553-564
( 2023)
ISSN: 1421-9875 [Electronic] Switzerland |
PMID | 36907179
(Publication Type: Meta-Analysis, Systematic Review)
|
Copyright | © 2023 S. Karger AG, Basel. |
Topics |
- Humans
- Stomach Neoplasms
(therapy)
- Helicobacter pylori
- Helicobacter Infections
(complications, drug therapy)
- Treatment Outcome
- Prognosis
|